Cellectis S.A.
CLLSNext catalyst
UCART20x22
B-cell Non-Hodgkin Lymphoma (B-NHL)
Get an email about CLLS's next catalysts
Track Cellectis (CLLS) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
CLLS Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | FQ end Sep/2026 | Call: tbd
UCART20x22 Phase 2 Est. Readout (NatHaLi-01)
Estimated primary completion for UCART20x22 trial (NCT05607420) in B-cell Non-Hodgkin Lymphoma (B-NHL). Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
UCART22
B-cell Acute Lymphoblastic Leukemia
UCART20x22
B-cell Non-Hodgkin Lymphoma (B-NHL)
CLLS52
B-cell Non-Hodgkin Lymphoma (B-NHL)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
UCART22 | Phase 2 | B-cell Acute Lymphoblastic Leukemia | - | - |
UCART20x22 | Phase 2 | B-cell Non-Hodgkin Lymphoma (B-NHL) | - | - |
CLLS52 | Phase 2 | B-cell Non-Hodgkin Lymphoma (B-NHL) | - | - |
Frequently asked questions
What is in Cellectis S.A.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in Cellectis S.A.'s (CLLS) pipeline across Phase 2. Its lead program is UCART20x22 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cellectis S.A.'s next FDA catalyst?→
Cellectis S.A.'s (CLLS) next tracked catalyst is a Phase 2 readout expected August 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CLLS biotech catalysts?→
Add CLLS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cellectis S.A.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.